Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Eva, Holtved"'
Autor:
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya‐Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcino
Externí odkaz:
https://doaj.org/article/59c4231e83f941f6a4719927e06f1ef1
Autor:
Gabriella Alexandersson von Döbeln, Gunnar Wagenius, Eva Holtved, Anne-Birgitte Jacobsen, Magnus Nilsson, Jingru Yu, Lene Baeksgaard
Publikováno v:
Cancer Treatment and Research Communications, Vol 24, Iss , Pp 100187- (2020)
Background: Chemoradiotherapy is standard treatment for localized oesophageal cancer unsuitable for surgery. We aimed to evaluate the efficacy of cetuximab in combination with chemoradiotherapy. Methods: This non-randomised multicentre phase II trial
Externí odkaz:
https://doaj.org/article/49e87bf593ef447999c7d68faeae26d0
Autor:
Yuko Kitagawa, Akira Takazawa, Yasuhiro Matsumura, Ioannis Xynos, Eva Holtved, Chih-Hung Hsu, Sung-Bae Kim, Yutaro Kubota, Chueh-Chuan Yen, Yuichiro Doki, Yasuo Hamamoto, Myung-Ju Ahn, Shigenori Kadowaki, Keisho Chin, Chen-Yuan Lin, Masanobu Takahashi, Byoung Chul Cho, Ken Kato, Morihito Okada
Supplementary Data from Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012c9054275c23855ab7b1aee7171098
https://doi.org/10.1158/1078-0432.22483407
https://doi.org/10.1158/1078-0432.22483407
Autor:
Yuko Kitagawa, Akira Takazawa, Yasuhiro Matsumura, Ioannis Xynos, Eva Holtved, Chih-Hung Hsu, Sung-Bae Kim, Yutaro Kubota, Chueh-Chuan Yen, Yuichiro Doki, Yasuo Hamamoto, Myung-Ju Ahn, Shigenori Kadowaki, Keisho Chin, Chen-Yuan Lin, Masanobu Takahashi, Byoung Chul Cho, Ken Kato, Morihito Okada
Supplementary Table from Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59b290bf57cedce0e34902700423d351
https://doi.org/10.1158/1078-0432.22483389.v1
https://doi.org/10.1158/1078-0432.22483389.v1
Autor:
Yuko Kitagawa, Akira Takazawa, Yasuhiro Matsumura, Ioannis Xynos, Eva Holtved, Chih-Hung Hsu, Sung-Bae Kim, Yutaro Kubota, Chueh-Chuan Yen, Yuichiro Doki, Yasuo Hamamoto, Myung-Ju Ahn, Shigenori Kadowaki, Keisho Chin, Chen-Yuan Lin, Masanobu Takahashi, Byoung Chul Cho, Ken Kato, Morihito Okada
Purpose:Limited long-term data are available on immune checkpoint inhibitor use in patients with advanced esophageal squamous cell carcinoma (ESCC). We report 3-year follow-up data from our study of nivolumab versus chemotherapy (paclitaxel or doceta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70bb54d97abc90463cdf2667b9770daf
https://doi.org/10.1158/1078-0432.c.6531132.v1
https://doi.org/10.1158/1078-0432.c.6531132.v1
Autor:
Morihito Okada, Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki, Chueh-Chuan Yen, Yutaro Kubota, Sung-Bae Kim, Chih-Hung Hsu, Eva Holtved, Ioannis Xynos, Yasuhiro Matsumura, Akira Takazawa, Yuko Kitagawa
Publikováno v:
Clinical Cancer Research. 28:3277-3286
Purpose: Limited long-term data are available on immune checkpoint inhibitor use in patients with advanced esophageal squamous cell carcinoma (ESCC). We report 3-year follow-up data from our study of nivolumab versus chemotherapy (paclitaxel or docet
Autor:
Ken Kato, Jaffer A. Ajani, Yuichiro Doki, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Freitas Melro Braghiroli, Eva Holtved, Mariela A. Blum Murphy, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Ian Chau, Yuko Kitagawa
Publikováno v:
Journal of Clinical Oncology. 41:290-290
290 Background: NIVO + chemo and NIVO + IPI demonstrated superior overall survival (OS) vs chemo in CheckMate 648 (NCT03143153), leading to approvals in the US, EU, Japan, and other countries. We report longer follow-up results. Methods: Adults with
Autor:
Yuichiro, Doki, Jaffer A, Ajani, Ken, Kato, Jianming, Xu, Lucjan, Wyrwicz, Satoru, Motoyama, Takashi, Ogata, Hisato, Kawakami, Chih-Hung, Hsu, Antoine, Adenis, Farid, El Hajbi, Maria, Di Bartolomeo, Maria I, Braghiroli, Eva, Holtved, Sandra A, Ostoich, Hye R, Kim, Masaki, Ueno, Wasat, Mansoor, Wen-Chi, Yang, Tianshu, Liu, John, Bridgewater, Tomoki, Makino, Ioannis, Xynos, Xuan, Liu, Ming, Lei, Kaoru, Kondo, Apurva, Patel, Joseph, Gricar, Ian, Chau, Yuko, Kitagawa, Rachna T, Shroff
Publikováno v:
Doki, Y, Ajani, J A, Kato, K, Xu, J, Wyrwicz, L, Motoyama, S, Ogata, T, Kawakami, H, Hsu, C H, Adenis, A, El Hajbi, F, Di Bartolomeo, M, Braghiroli, M I, Holtved, E, Ostoich, S A, Kim, H R, Ueno, M, Mansoor, W, Yang, W C, Liu, T, Bridgewater, J, Makino, T, Xynos, I, Liu, X, Lei, M, Kondo, K, Patel, A, Gricar, J, Chau, I, Kitagawa, Y & CheckMate 648 Trial Investigators 2022, ' Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma ', The New England Journal of Medicine, vol. 386, no. 5, pp. 449-462 . https://doi.org/10.1056/NEJMoa2111380
BACKGROUND: First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esoph
Autor:
Troels Bechmann, M.H. Nielsen, Tamás Lörincz, Marie Louise Holm Milo, Axel Cosmus Pyndt Diederichsen, Eva Holtved, Ebbe Laugaard Lorenzen, Marianne Nordsmark, Birgitte Vrou Offersen, Petra Witt Nyström, Tine Schytte, Christian Rønn Hansen, Mirjana Josipovic, Mette Pøhl, Maja V. Maraldo, E.S. Yates, Hanne Krogh Rose
Publikováno v:
Milo, M L H, Offersen, B V, Bechmann, T, Diederichsen, A C P, Hansen, C R, Holtved, E, Josipovic, M, Lörincz, T, Maraldo, M V, Nielsen, M H, Nordsmark, M, Nyström, P W, Pøhl, M, Rose, H K, Schytte, T, Yates, E S & Lorenzen, E L 2020, ' Delineation of whole heart and substructures in thoracic radiation therapy : National guidelines and contouring atlas by the Danish Multidisciplinary Cancer Groups ', Radiotherapy and Oncology, vol. 150, pp. 121-127 . https://doi.org/10.1016/j.radonc.2020.06.015
Background and purpose This study presents Danish consensus guidelines for delineation of the heart and cardiac substructures across relevant Danish Multidisciplinary Cancer Groups. Material and methods Consensus guidelines for the heart and cardiac
Autor:
Masanobu Takahashi, Sung Bae Kim, Yutaro Kubota, Yuko Kitagawa, Morihito Okada, Chen Yuan Lin, Eva Holtved, Chueh Chuan Yen, Yasuo Hamamoto, Mamoru Kodani, Ken Kato, Ioannis Xynos, Chih-Hung Hsu, Myung-Ju Ahn, Yuichiro Doki, Keisho Chin, Shigenori Kadowaki, Byoung Chul Cho
Publikováno v:
Kato, K, Cho, B C, Takahashi, M, Okada, M, Lin, C Y, Chin, K, Kadowaki, S, Ahn, M J, Hamamoto, Y, Doki, Y, Yen, C C, Kubota, Y, Kim, S B, Hsu, C H, Holtved, E, Xynos, I, Kodani, M & Kitagawa, Y 2019, ' Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3) : a multicentre, randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 20, no. 11, pp. 1506-1517 . https://doi.org/10.1016/S1470-2045(19)30626-6
Background: Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. We report the final analysis from our study of the immune checkpoint PD-1 inhibitor nivolumab versus chemotherapy in pat